Pfizer Advances in Cancer Cell Therapy with Allogene Agreement – Market Realist
Market Realist |
Pfizer Advances in Cancer Cell Therapy with Allogene Agreement
Market Realist According to the terms of the agreement, upon completion of the transaction, Allogene has rights to Pfizer's 16 pre-clinical CAR–T assets. Those assets are licensed from Servier, a French pharmaceutical company; Cellectis (CLLS), a French cell therapy … |
